10x Genomics, Inc. (TXG)
Market Cap | 3.18B |
Revenue (ttm) | 625.45M |
Net Income (ttm) | -264.30M |
Shares Out | 119.71M |
EPS (ttm) | -2.23 |
PE Ratio | n/a |
Forward PE | 196.08 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,598,357 |
Open | 27.57 |
Previous Close | 26.97 |
Day's Range | 26.40 - 28.25 |
52-Week Range | 24.60 - 63.57 |
Beta | 1.94 |
Analysts | Buy |
Price Target | 49.33 (+85.73%) |
Earnings Date | Apr 30, 2024 |
About TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; si... [Read more]
Financial Performance
In 2023, 10x Genomics's revenue was $618.73 million, an increase of 19.81% compared to the previous year's $516.41 million. Losses were -$255.10 million, 53.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for TXG stock is "Buy." The 12-month stock price forecast is $49.33, which is an increase of 85.73% from the latest price.
News
Vizgen Announces Significant Win in Ongoing Patent Litigation Against 10x Genomics and Harvard University
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen, Inc., the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, has achieved a significant victor...
10x Genomics to Present at the BofA Securities 2024 Healthcare Conference
PLEASANTON, Calif. , May 2, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in ...
Curio Bioscience Reports Clarifying Decision From European Unified Patent Court (UPC)
PALO ALTO, Calif.--(BUSINESS WIRE)--Curio Bioscience, a leading innovator of high-precision tools for the life sciences industry, today announced that a decision in a court case has been made. The Eur...
10x Genomics Reports First Quarter 2024 Financial Results
PLEASANTON, Calif. , April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31...
10x Genomics to Report First Quarter 2024 Financial Results on April 30, 2024
PLEASANTON, Calif. , April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first q...
10x Genomics Commercially Launches Visium HD Spatial Gene Expression Assay
Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution PLEASANTON, Calif. , March 26, 2024 /PRNewswire/ -- 10x Genomics...
10x Genomics Expands Xenium Menu with Multi-Modal Cell Segmentation Kit and Immuno-Oncology Gene Panel
Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue ...
10x Genomics Begins Commercial Shipments of Chromium GEM-X Products
The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost PLEASANTON, Calif. , March 13, 2024 /PRNewswire/ -- 1...
Vizgen Announces Denial of 10x Genomics' Petition for Inter Partes Review of Vizgen-Licensed Patent Currently Asserted Against 10x's Xenium Platform
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vizgen announces the denial of 10x Genomics' petition for Inter Partes Review of the Vizgen-licensed patent asserted against 10x's Xenium Platform.
10x Genomics to Present at the 44th Annual TD Cowen Health Care Conference
PLEASANTON, Calif. , Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate i...
10x Genomics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Outlook for 2024
Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif. , Feb. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in ...
10x Genomics Expands Leadership in Single Cell Analysis with Launch of GEM-X Technology
GEM-X, the next generation of the company's leading single cell technology architecture, enables higher performance at larger scale and lower cost Pre-orders now open for first two Chromium products p...
10x Genomics to Showcase New Cutting-Edge Technologies and Highlight Innovation Roadmap at 2024 AGBT General Meeting
New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology PLEASANTON, Calif. , Feb. 5, 2024 /PRNewswire/ -- 10x Genomic...
TXG Alert: Johnson Fistel Announces Investigation of 10x Genomics for Potential Securities Law Violations
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP is investigating 10x Genomics, Inc. (NASDAQ: TXG) (“10x Genomics” or the “Company”) for potential securities law violations. Shareholders who have incur...
10x Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024
PLEASANTON, Calif. , Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth q...
10x Genomics Announces Preliminary Fourth Quarter and Full Year 2023 Results
PLEASANTON, Calif. , Jan. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth qu...
10x Genomics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PLEASANTON, Calif. , Dec. 21, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will present at th...
10x Genomics Launches Xenium Catalyst Network
Founding Network Members Will Accelerate Access to Proof-of-Concept Data for Prospective Xenium Customers Worldwide PLEASANTON, Calif. , Dec. 20, 2023 /PRNewswire/ -- 10x Genomics, Inc. , (Nasdaq: TX...
Integrative Study Conducted by 10x Genomics Combines Single Cell, Spatial and In Situ Analyses to Investigate Tumor Invasiveness
A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platforms PLEASANTON, Calif. , Dec. 19, 2023 /PRNew...
High Sensitivity and Specificity of the Xenium Platform from 10x Genomics Outperforms NanoString's CosMx and Vizgen's Merscope in Benchmarking Preprint
Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif. , Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: ...
10x Genomics and NIH CARD to Create Comprehensive Single Cell Atlas of the Human Brain
PLEASANTON, Calif. , Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alz...
NanoString stock sinks nearly 50% after losing patent lawsuit case against 10x Genomics
Shares of Seattle-based publicly traded biotech company NanoString Technologies fell nearly 50% to an all-time low on Monday following its loss in a patent infringement case against 10x Genomics.
10x Genomics Wins Another Patent Infringement Case Against NanoString Technologies
Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing Serial ...
OWKIN Integrates 10x Genomics Spatial Omics and Single-Cell Technologies to the MOSAIC Study
PLEASANTON, Calif. and PARIS , Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell t...
10x Genomics Reports Third Quarter 2023 Financial Results
PLEASANTON, Calif. , Nov. 2, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September ...